Last reviewed · How we verify
Carbetocin infusion
Carbetocin is a synthetic oxytocin analogue that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown.
Carbetocin is a synthetic oxytocin analogue that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown. Used for Prevention and treatment of postpartum hemorrhage, Promotion of milk letdown in lactation.
At a glance
| Generic name | Carbetocin infusion |
|---|---|
| Also known as | Duratocin |
| Sponsor | Ciusss de L'Est de l'Île de Montréal |
| Drug class | Oxytocin receptor agonist |
| Target | Oxytocin receptor (OXTR) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics/Gynecology |
| Phase | FDA-approved |
Mechanism of action
Carbetocin mimics the natural hormone oxytocin by activating oxytocin receptors on uterine smooth muscle, triggering sustained contractions that help control postpartum hemorrhage and facilitate milk ejection during lactation. It has a longer duration of action and more selective receptor binding compared to natural oxytocin, making it effective at lower doses.
Approved indications
- Prevention and treatment of postpartum hemorrhage
- Promotion of milk letdown in lactation
Common side effects
- Hypertension
- Headache
- Nausea
- Flushing
- Tachycardia
Key clinical trials
- Effects of Carbetocin and Oxytocin Used in Cesarean Sections on Postoperative Pain
- Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery (NA)
- A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects (PHASE1)
- Comparing Tranexamic Acid Versus Ecbolics in Preventing Hemorrhage During and After Cesarean Section (NA)
- Efficacy of Carbetocin Versus Oxytocin Plus Misoprostol in Decreasing Blood Loss During Cesarean Section (PHASE4)
- Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients Undergoing Caesarean Section (PHASE4)
- Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections (PHASE4)
- Methods Decreasing Bleeding in Open Myomectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbetocin infusion CI brief — competitive landscape report
- Carbetocin infusion updates RSS · CI watch RSS
- Ciusss de L'Est de l'Île de Montréal portfolio CI